Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212645 | 0.91 | SIGMAR1 (0.53) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL2213070 | 0.89 | UTS2R (0.64) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL2214839 | 0.87 | UTS2R (0.65) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL2211108 | 0.85 | UTS2R (0.62) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL2212835 | 0.84 | MCHR1 (0.55) | UTS2RSIGMAR1MCHR1CCR3MEN1 | |
| SCHEMBL2213240 | 0.84 | USP2 (0.62) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL12511833 | 0.82 | CCR3 (0.47) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL2208484 | 0.81 | CCR3 (0.49) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL12511780 | 0.80 | SIGMAR1 (0.61) | UTS2RSIGMAR1MCHR1CCR3CCR1 | |
| SCHEMBL2210772 | 0.80 | UTS2R (0.47) | UTS2RSIGMAR1MCHR1CCR3CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | UTS2R 2154/4885SIGMAR1 2000/4885MCHR1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.